Drugs News and Research

RSS

Obese and overweight men spend 3.5 times more on prescription drugs than normal-weight men

As middle-aged men’s weight goes up, so do their monthly costs for prescription drugs to treat heart disease risk factors and weight-related conditions, according to research presented at the American Heart Association’s Scientific Sessions 2004.

8 Nov 2004

Coronary stents have no impact on mortality over the long term

While the placement of stents in newly reopened coronary arteries has been shown to reduce the need for repeat angioplasty procedures, researchers from the Duke Clinical Research Institute have found that stents have no impact on mortality over the long term.

8 Nov 2004

Dopamine in the brain plays a key role in how we make choices

Researchers at the University of Colorado at Boulder studying Parkinson's disease patients found strong evidence that dopamine in the brain plays a key role in how people implicitly learn to make choices that lead to good outcomes, while avoiding bad ones.

8 Nov 2004

Testosterone may impede immunity

Decreasing testosterone boosts immunity because testosterone helps control T-lymphocytes, the attack cells of the immune system, according to Mayo Clinic-led research in laboratory animals.

8 Nov 2004

Researchers find two locations in the human genome that may harbor genes that increase the risk of Alzheimer’s disease

Researchers at Columbia University Medical Center have found two locations in the human genome that may harbor genes that increase the risk of Alzheimer’s disease. If confirmed, they will be the first genes linked to Alzheimer’s disease since ApoE4 was discovered in 1993.

8 Nov 2004

Remicade (infliximab) is able to reverse the symptoms of rheumatoid arthritis

A new study published today in Arthritis & Rheumatism demonstrates that Remicade (infliximab) is able to reverse the symptoms of the debilitating disease rheumatoid arthritis (RA) in patients who are newly diagnosed.

5 Nov 2004

Atenolol beta-blocker may not be effective in reducing heart attacks

A study published in this weeks issue of THE LANCET suggest that atenolol - one of the most widely prescribed beta-blockers for reducing blood pressure - may not be effective in reducing heart attacks or death from cardiovascular causes.

5 Nov 2004

Vioxx linked with risk of cardiovascular disease

With the support of the National Research Programme (Musculoskeletal Health - Chronic Pain) , researchers at the University of Berne analysed the data in publicly available studies on the anti-inflammatory drug Vioxx.

5 Nov 2004

Celebrex may one day be used to prevent and even treat breast tumors

The anti-inflammatory drug Celebrex, or celecoxib, reduces tumor mass by encouraging cell death and discouraging both cell proliferation and the sprouting of new blood vessels that feed growing tumors, according to a study reported in the November issue of Molecular Cancer Research.

5 Nov 2004

Body's 'internal marijuana': A new target for treatment of schizophrenia, Parkinson's?

“Endocannabinoids” is an impressive word that sounds like the name for a group of tribal warriors or an ancient people. Actually, it is the scientific term for beneficial molecules produced in the brain that act as “a sort of internal marijuana in our system

4 Nov 2004

alpha4 may prove to be useful target for smoking addiction therapies

Nicotine is responsible for more than four million smoking-related deaths each year. Yet people still smoke. Why? One reason is the stranglehold of addiction, started when nicotine enhances the release of a neurotransmitter called dopamine

4 Nov 2004

Cellular vehicle delivers drugs directly into cancer cells

Researchers at The University of Texas M. D. Anderson Cancer Center have perfected a delivery system for anticancer treatment that zeroes in on a tumor and becomes part of its supporting tissue.

4 Nov 2004

Trial of new type of drug that attacks amyloid

Neuroscientists at the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia will begin a clinical trial testing a new type of drug that attacks amyloid, the protein substance that accumulates in the brains of Alzheimer’s disease patients.

4 Nov 2004

Ecstasy use down among America's youth

The Substance Abuse and Mental Health Services Administration's (SAMHSA's) just-released 2003 National Survey on Drug Use and Health (NSDUH) reports the number of current ecstasy users decreased between 2002 and 2003, from 676,000 (0.3 percent) to 470,000 (0.2 percent).

4 Nov 2004

Pfizer licenses drug from University of Rochester for treatment of hot flashes

The University of Rochester has signed a license agreement with Pfizer which will allow Pfizer to market a specific class of non-hormonal drugs for the treatment of hot flashes associated with menopause.

4 Nov 2004

Crystal structure of protein AIRs kinase uncovered

Cornell University researchers, who are trying to understand how proteins evolve and function by looking at their structural features, have uncovered the crystal structure of a protein involved in making the building blocks of DNA correctly.

4 Nov 2004

Cyclooxygenase (COX) inhibitors tested in both prevention and treatment clinical trials

Numerous compounds are examined by the National Cancer Institute (NCI) for their potential to prevent or treat cancer. One class of compounds, cyclooxygenase (COX) inhibitors, is currently being tested in both prevention and treatment clinical trials.

4 Nov 2004